Rockwell Medical Inc (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that two Triferic abstracts have been selected by the National Kidney Foundation(NKF) for presentation at their Spring Clinical Meetings to be held April 27 – May 1, 2016 at the Hynes Convention Center, Boston, MA. Triferic is the Company’s iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
The following abstracts have been accepted to be printed in the American Journal of Kidney Disease and for poster presentation at the NKF meetings:
- Triferic Maintains Hemoglobin and Iron Balance Long Term: Open-Label Phase III Extension Studies
- Pharmacology of Triferic in Chronic HD Patients. (Original Source)
Shares of Rockwell Medical closed last Friday at $7.36. RMTI has a 1-year high of $18.90 and a 1-year low of $7.03. The stock’s 50-day moving average is $9.73 and its 200-day moving average is $11.53.
On the ratings front, Rockwell Medical has been the subject of a number of recent research reports. In a report issued on December 8, Oppenheimer analyst Ling Wang assigned a Buy rating on RMTI, with a price target of $26, which implies an upside of 253.3% from current levels. Separately, on November 10, Brean Murray Carret’s Jonathan Aschoff reiterated a Sell rating on the stock and has a price target of $4.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Jonathan Aschoff have a total average return of -21.5% and -11.9% respectively. Wang has a success rate of 15.0% and is ranked #3562 out of 3582 analysts, while Aschoff has a success rate of 32.2% and is ranked #3543.
Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.